Receives cash payment of $ 3.45 mil. from Bolar to settle its May 8 suit seeking damages for the generic firm's fraudulent marketing of a version of Norwich-Eaton's Macrodantin (nitrofurantoin). The complaint sought treble damages. Bolar's generic version generated sales of about $ 13 mil., according to the company's statements when it withdrew the ANDA for the product in 1989. So far this year, Bolar has paid out $ 56 mil. to settle lawsuits and still faces litigation from Warner-Lambert, Barr Labs and an SEC investigation. . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth